Roche Partners with AREVA in Creation of Radio-Immunotherapy
Roche (OTC: RHHBY) and AREVA Med, a subsidiary of AREVA, announced today that they have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.